Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
The Indianapolis-based forensics, clinical and pharmaceutical testing firm, led by CEO Michael Evans, plans to invest $74
million to acquire and equip
an existing 90,000-square-foot building in Woodland Corporate Park near West 79th Street and Interstate 465.
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based
life sciences trade group BioCrossroads.
Cold storage might become a hot business for a building contractor.
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
More emerging life science companies have found life in the form of federal
Small Business Innovation Research grants.
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer’s
disease and muscular dystrophy.
Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individuals
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
Executives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
Lilly executives want to make biotech their top focus.
Three months after launching an initiative to boost drug-development firms in Indiana, officials at BioCrossroads have written
a report that attempts to show in detail the vast market opportunity they see.
For the last two months, two academics at Indiana University and Purdue University have been discussing how the institutions
can work together to rev up research in medicine and life sciences and, in the process, boost Indiana’s economy.
Four former top scientists at Eli Lilly and Co. have formed a Carmel-based company to develop diabetes therapies–a venture observers say has the potential to become the kind of blockbuster success BioCrossroads was built to stimulate.
Labs are nearing capacity at Strand Analytical Laboratories, which provides forensic and paternity DNA testing. In the second year of Scott Newman’s business, the former prosecutor predicts 2007 revenue will reach $4 million.